Publications by authors named "A Verbiest"

Article Synopsis
  • Apraglutide is a new long-acting GLP-2 analog being tested for short bowel syndrome with intestinal failure (SBS-IF) in a phase 2 study.
  • The study involved 9 adult patients receiving weekly injections of apraglutide over 52 weeks, measuring its safety and effects on their nutritional needs and intestinal health.
  • Results showed significant improvements, including a 52% decrease in parenteral support needs and enhanced absorption of nutrients, alongside a manageable safety profile with mostly mild adverse events.
View Article and Find Full Text PDF

An important challenge in the real-world management of patients with advanced clear-cell renal cell carcinoma (aRCC) is determining who might benefit from immune checkpoint blockade (ICB). Here we performed a comprehensive multiomics mapping of aRCC in the context of ICB treatment, involving discovery analyses in a real-world data cohort followed by validation in independent cohorts. We cross-connected bulk-tumor transcriptomes across >1,000 patients with validations at single-cell and spatial resolutions, revealing a patient-specific crosstalk between proinflammatory tumor-associated macrophages and (pre-)exhausted CD8 T cells that was distinguished by a human leukocyte antigen repertoire with higher preference for tumoral neoantigens.

View Article and Find Full Text PDF
Article Synopsis
  • Short bowel syndrome (SBS) happens when a person has less than 200 cm of small intestine left, often due to surgery.
  • This condition can lead to serious problems, like not being able to absorb food properly and needing special nutrition through a vein (called parenteral support).
  • The review talks about how having part of the colon helps with digestion and could change how treatments work for people with SBS, especially those with a colon still connected.
View Article and Find Full Text PDF

Unlabelled: Highly effective systemic treatments have globally improved outcomes in metastatic clear-cell renal cell carcinoma (m-ccRCC). However, despite many efforts, reliable biomarkers predicting individual responses are currently lacking. Moreover, mixed responses are commonly observed.

View Article and Find Full Text PDF